Michel Ng

Costs of telaprevir‐based triple therapy for hepatitis C: $189,000 per sustained virological response

A. Branch, V. Martel-Laferrière, A. Moskowitz, 2014, Hepatology.

Real-World Sustained Virologic Response Rates of Sofosbuvir-Containing Regimens in Patients Coinfected With Hepatitis C and HIV.

A. Branch, D. Dieterich, T. Schiano, 2016, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Hepatic decompensation/serious adverse events in post-liver transplantation recipients on sofosbuvir for recurrent hepatitis C virus.

A. Branch, S. Friedman, D. Dieterich, 2016, World journal of gastroenterology.

Real-world cure rates for hepatitis C virus treatments that include simeprevir and/or sofosbuvir are comparable to clinical trial results

A. Branch, S. Friedman, D. Dieterich, 2017, World journal of virology.

Hepatitis C Virus Treatment in HIV-Coinfected Patients: No Longer Different From Monoinfection Treatment.

D. Dieterich, Bevin Hearn, J. Lawler, 2014, Gastroenterology & hepatology.

795 REAL WORLD COSTS OF TELAPREVIR-BASED TRIPLE THERAPY, INCLUDING COSTS OF MANAGING ADVERSE EVENTS, AT THE MOUNT SINAI MEDICAL CENTER, NY: $147,000 PER EOT

A. Branch, V. Martel-Laferrière, D. Dieterich, 2013 .

Factors associated with success of telaprevir- and boceprevir-based triple therapy for hepatitis C virus infection

A. Branch, V. Martel-Laferrière, D. Dieterich, 2017, World journal of hepatology.

1137 EFFECTIVENESS OF HCV TRIPLE THERAPY WITH TELAPREVIR IN NEW YORK CITY

A. Branch, V. Martel-Laferrière, M. Vachon, 2012 .